Even though glycemic levels are under control in type 1 diabetes (T1D) patients, they may experience "glycemic excursions" (blood sugar or glucose or glycemic levels changing from hyperglycemic or high levels to hypoglycemic or low levels) with insulin. A study funded by dapagliflozin drug (a SGLT2 inhibitor) development partners, Bristol-Myers Squibb and AstraZeneca, shows marked reduction in blood sugar levels in most of the type 1 diabetes (T1D) patients with dapagliflozin drug. Currently, dapagliflozin drug was being used to treat patients with type 2 diabetes (T2D).
Researchers have conducted a 24 week study, named as Dapagliflozin in Patients with Inadequately Controlled Type 1 diabetes (T1D) study (DEPICT-1), the first Phase 3 trial, in 17 countries, including the United States to find out dapagliflozin drug efficacy and safety as an adjunct treatment for insulin, for the treatment of type 1 diabetes (T1D) patients with inadequately controlled blood glucose levels. The total number of the participants were 833, aged between 18 and 75 years.
The study results show approximately 50 percent of the type 1 diabetes (T1D) patients have successfully reduced their A1C levels by more than 0.5 percent without low blood sugar levels (hypoglycemia) events. The authors say that the dapagliflozin drug is eligible for license by the United States FDA as an antidiabetic agent for type 1 diabetes (T1D) patients as the drug reduces HbA1c levels by about 0.5 percent. But they say the drug needs further studies to confirm the current study findings.
Manufacturers likely to apply for United States FDA licensing after getting the results of DEPICT-1 at 56-week study and DEPICT-2, a parallel dapagliflozin medication study. Senior author of the study was Professor Paresh Dandona, MD, PhD, chief of endocrinology, diabetes and metabolism, Jacobs School of Medicine and Biomedical Sciences, the University at Buffalo.
A study done by researchers at the Institute of Environmental Medicine (IMM), Karolinska Institutet, Sweden shows twice likely risk of the development of diabetes (apart from the risk of high blood pressure BP or hypertension) among those people who consume more salt (as 40 percent of salt is sodium). Researchers say salt directly affects insulin resistance.
The study results show 43 percent increased risk for the development of type 2 diabetes (T2D) with 2.5 grams of extra salt consumption (equal to 1 gram of sodium) per day. The study also shows 72 percent increased risk for the development of type 2 diabetes (T2D) in individuals who consume more than 7.3 grams of salt per day when compared with individuals who consume less than 6 grams of salt per day.
Individuals with human leukocyte antigen (HLA) protein and consuming high salt (more than 3.15 grams of salt per day) are at four times higher risk of the development of type 1.5 diabetes or latent autoimmune diabetes in adults (LADA) compared with individuals consuming low (less than 2.4 grams of salt per day).
Lead authors of the study were Bahareh Rasouli, the Institute of Environmental Medicine (IMM). The study findings were presented at the annual meeting of the European Association for the Study of Diabetes (EASD) 2017, Lisbon, Portugal and published on September 14, 2017, in the Diabetologia. Title of the article was "Sodium (salt) intake is associated with a risk of developing type 2 diabetes."
Type 1.5 diabetes : Type 1.5 diabetes or latent autoimmune diabetes in adults (LADA) is a type 1 diabetes (T1D) which appears during adulthood. The onset of LADA in adulthood is slower when compared to the onset of type 1 diabetes (T1D) in childhood. This occurs due to the destruction or damage to the insulin-producing beta cells in the pancreas.
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.